NovoCure Ltd Files 8-K with Corporate Updates

TL;DR

NovoCure filed an 8-K on 8/28/25, confirming its Jersey HQ and contact info.

AI Summary

NovoCure Ltd. filed an 8-K on August 28, 2025, reporting information under Regulation FD and including financial statements and exhibits. The filing details the company's principal executive offices located at No. 4 The Forum, Grenville Street, St. Helier, Jersey JE2 4UF, with a business phone number of +44 (0) 15 3475 6700. The company was formerly known as Novocure Ltd, with a name change effective June 15, 2015.

Why It Matters

This filing provides essential corporate information and disclosures for NovoCure Ltd., impacting investors' understanding of the company's structure and reporting. It confirms the company's official address and contact details.

Risk Assessment

Risk Level: low — The filing is a routine corporate disclosure and does not contain information that inherently increases risk.

Key Players & Entities

• NovoCure Ltd (company) — Registrant
• Novocure Ltd (company) — Former company name
• No. 4 The Forum, Grenville Street St. Helier Jersey JE2 4UF (location) — Principal Executive Offices
• + 44 (0) 15 3475 6700 (phone_number) — Registrant's telephone number
• August 28, 2025 (date) — Date of Report
• 20150615 (date) — Date of name change

FAQ

Filing Documents

• nvcr-20250828.htm (8-K) — 24KB
• 0001645113-25-000032.txt ( ) — 137KB
• nvcr-20250828.xsd (EX-101.SCH) — 2KB
• nvcr-20250828_lab.xml (EX-101.LAB) — 21KB
• nvcr-20250828_pre.xml (EX-101.PRE) — 12KB
• nvcr-20250828_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On August 28, 2025, Novocure GmbH, a subsidiary of NovoCure Limited (the "Company" or "Novocure"), as sponsor, notified trial sites that it has decided to terminate its LUNAR-4 trial. LUNAR-4 is a phase 2, single arm, open-label, multinational study of Tumor Treating Fields concomitant with pembrolizumab for the treatment of metastatic non-small cell lung cancer (NSCLC) previously treated with a PD-1/PD-L1 inhibitor and platinum-based chemotherapy. The availability of real-world evidence will enable Novocure to achieve the objectives of LUNAR-4 without the need for an interventional clinical study. This decision is not related to any safety concerns. The information contained in this Item 7.01 of this Current Report shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NovoCure Limited (Registrant) Date: August 28, 2025 By: /s/ Christoph Brackmann Name: Christoph Brackmann Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR